Relates to the labeling of mifepristone, misoprostol, and their generic alternatives

Introduced

In Committee

Floor

Crossed Over

Passed

Enacted

Overview Bill text 2 Compare versions History 8 Sponsors

Version comparison

2 versions

Sign in to read the full text

The document summary and details above are public. The full text is available to signed-in accounts.

Create a free account Sign in

PASSAGE PROBABILITY

1% Unlikely

Why this number

Stage base Amended — base rate 13%, measured from NY's completed sessions
Momentum +1 54/100 from the pace of recorded action
Time since last action -22 626 days quiet

A transparent scoring model over stage, momentum, recency, sponsorship and recorded votes — not a trained predictor. Treat it as a way to rank attention, not as a forecast.